On 11 October, Ardelyx reported positive results from a second pivotal Phase III...
- Tenapanor likely to makes waves in IBS-C space
- Stand Up To Cancer initiates ten clinical trial projects for oncology
- OncoArendi to evaluate OATD-01 in Phase I trial for asthma
- GSK’s Shingrix set to disrupt the herpes zoster vaccine marketplace
- Fulfilling the main unmet needs in prostate cancer will open the way for new ones
Tenapanor likely to makes waves in IBS-C space
On 11 October, Ardelyx reported positive results from a second pivotal Phase III trial (T3MPO-2) assessing the efficacy and safety of its lead product, tenapanor, which is under development for treatment of irritable bowel syndrome with constipation.
Stand Up To Cancer initiates ten clinical trial projects for oncology
Entertainment Industry Foundation's (EIF) Stand Up To Cancer (SU2C) initiative has launched ten SU2C Catalyst clinical trial projects for the treatment of different types of the disease.
Verzenio (abemaciclib) for the Treatment of Metastatic Breast Cancer
Verzenio™ (abemaciclib) is a cyclin-dependent kinases (CDK) 4 and 6 inhibitor indicated for the treatment of women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced or metastatic breast cancer.
Benefits of Trehalose
Products such as monoclonal antibodies (mAb), fusion proteins, peptides, vaccines, antibody drug conjugulates (ADC) and stem cells benefit from the stabilising effects of Trehalose.
OncoArendi to evaluate OATD-01 in Phase I trial for asthma
Polish biopharmaceutical company OncoArendi Therapeutics is set to conduct a Phase I clinical trial of its lead drug candidate OATD-01 to treat patients suffering from asthma.
GSK’s Shingrix set to disrupt the herpes zoster vaccine marketplace
On September 13, GlaxoSmithKline (GSK) announced that the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend the approval of its investigational vaccine, Shingrix (zoster vaccine, recombinant [adjuvanted]), for the prevention of herpes zoster (HZ) in adults ≥50 years of age.
Fulfilling the main unmet needs in prostate cancer will open the way for new ones
Among the current unmet needs in prostate cancer, the lack of therapeutic options for non-metastatic castration-resistant prostate cancer (nmCRPC) patients and the need to delay the onset of castration-resistant disease in metastatic hormone-naïve prostate cancer (mHNPC) are two of the most pressing ones.
Characterisation Information of Critical Excipients for Sourcing Critical Raw Materials
The increasing complexity of large molecule and cell-based therapeutics calls for an evolution in our understanding of the impurity and functional contributions of each formulation component.
Lartruvo (olaratumab) for the Treatment of Soft Tissue Sarcoma
Developed by Eli Lilly and Company, Lartruvo (olaratumab) in combination with doxorubicin is indicated for the treatment of soft tissue sarcoma (STS) in adult patients. The drug is available as a 10mg/ml injection.
Go Beyond With Your Discoveries with Softigel Product Development and Contract Manufacturing Services
Part of the Procaps Group and one of the world's largest manufacturers, Softigel shows its deep knowledge of gelatin formation in its softgels expertise.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.